Opinion|Videos|February 7, 2025
Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
Panelists discuss how isatuximab- and daratumumab-based quadruplet regimens compare in patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM), with a particular focus on minimal residual disease (MRD) negativity data from the IMROZ and CEPHEUS trials, presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do isatuximab-based regimens compare with daratumumab-based quadruplet regimens in patients with transplant-ineligible/deferred NDMM?
- Please comment on the latest results and approval from the IMROZ study evaluating Isa-VRd vs VRd in transplant-ineligible/deferred NDMM.
- What is the significance of MRD negativity as a primary outcome in studies presented at ASH 2024?
- CEPHEUS, MRD Negativity
- IMROZ, MRD Negativity
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5